The bar low­ers yet again for PRV prices, with Ky­owa/Ul­tragenyx sell­ing at $80.6M

Are we back where we start­ed with the price tag of pri­or­i­ty re­view vouch­ers? Their dwin­dling val­ue slid fur­ther south this morn­ing, with news that Ky­owa Hakko Kirin and its part­ner Ul­tragenyx sold off their rare dis­ease PRV for $80.6 mil­lion. That’s a far cry from the go-go days of Ab­b­Vie’s his­toric $350 mil­lion PRV pur­chase in 2015.

Ky­owa re­vealed Wednes­day morn­ing that the duo sold its PRV for a rare pe­di­atric dis­ease drug to an undis­closed buy­er dur­ing Q2, ac­cord­ing to a Bio­Cen­tu­ry re­port. The com­pa­nies re­ceived the vouch­er in April when the FDA ap­proved Crysvi­ta to treat ab­nor­mal­ly low lev­els of phos­phate in the blood.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.